A fluorescence active
nanosystem capable of targeting specific
receptors of cancer cells with or without a biorecognition element
is advantageous for biosensor studies. Herein, a naturally occurring
anticancer drug, amygdalin (synthetic form: Laetrile, a misnomer:
vitamin B17), has been modified on the surface of carbon quantum dots,
prepared by a hydrothermal method, to probe β-glucosidase activity.
Despite its cyanide toxicity, amygdalin is recently revived to be
an anticancer molecule, and the risk factor can be optimized by understanding
its binding efficiency with β-glucosidase in the cancer cells.
In this study, an in vitro biorecognition pattern
of amygdalin-functionalized carbon quantum dots (Amy@CQDs) toward
β-glucosidase is typically evaluated by an aggregation-induced
fluorescence emission mechanism. The optical functionality and structural
integrity of CQDs before and after functionalization with amygdalin
are comprehensively studied by spectroscopic and microscopic techniques.
Our results demonstrate that Amy@CQDs is a stable hydrophilic graphitic
carbon nanostructure exhibiting selective fluorescence quenching upon
interaction with β-glucosidase, enabling the lowest detection
limit of 134 nM. Hydrolysis products of amygdalin mediated by β-glucosidase
were further confirmed by HPLC and colorimetric methods, indicating
the selective binding of the prepared Amy@CQDs, which may find a useful
application in cancer diagnosis and therapeutics.